Eloi, J., Chabanne, L., Whittell, G
About Our Editorial Team Written By, Danielle Mahri, Staff Writer Danni is a degree-educated content writer who works closely with our clinical and customer services teams to ensure every article is well-researched and accurate
With $222M of cash, no debt, positive FCF, expanding margins, and multiple new products not reflected in guidance, the setup remains very compelling in my view
UTIs in Special Populations Urinary Tract Infections dont affect everyone the same way
Key drivers behind GLP-1 and addiction research include: Rapid expansion in the use of GLP-1 medications such as semaglutide (Ozempic and Wegovy) and tirzepatide (Maunjaro and Zepbound) Reports of changes in cravings, alcohol use, or reward-seeking behaviors beyond weight loss Increased public conversation and clinical curiosity about psychological and behavioral effects Scientific interest in GLP-1 activity within reward pathways and dopamine signaling Recognition that appetite regulation and addiction involve shared neural mechanisms This research is still emerging, and findings should be interpreted with caution
/media/img/mt/2026/07/PeptideGoldRush/original.png){kind=icon}
